staphefekt™: sustainable antibacterial therapy with endolysins
TRANSCRIPT
10th Medical Innovations Summit | The Royal Society of Medicine | London | Saturday 18th April 2015
Staphefektsustainable antibacterial therapy with endolysins
Mark Offerhaus, CEO MicreosBjorn Herpers, Clinical microbiologist
©2015 Micreos
“We believe the environmental hit in AD relates to staphylococci and their biofilms,
which occlude sweat ducts [...leading…] to inflammation and pruritis.”
(Allen, JAMA Dermatol. 2014)
“Staphylococcus aureus […] produces pain
by directly activating sensory neurons that modulate inflammation.”
(Chiu, Nature 2013)
“The proportion of […] particularly S. aureus was greater during disease flares
[…] and correlated with worsened disease severity.”
(Kong, Genome Res. 2012)
“Antibiotic resistance is one of the most pressing
public health issues facing the world today.”
(President Obama)
“Antimicrobial resistance requires action across
all government sectors and society... People with
MRSA are 64% more likely to die from infection
than people with a non-resistant form...
The problem is so serious that it threatens the
achievements of modern medicine”
(World Health Organization)
Lysis of bacterial cell by endolysins
Critical step in replication cycle
Resistance in this step unlikely
Endolysins (Staphefekt) lyse cell from outside
No phage needed, only protein
0%
25%
50%
75%
100%
0 20 40 60
Decre
ase
in o
pti
cal
den
sit
y
t (minutes)
S. epidermidis
MSSA
MRSA
0
1000
2000
3000
4000
5000
0 5 10 15 20
MIC
Number of exposition cycles
Lysostaphin
Mupirocin
Staphefekt
Skin Colonization
Irritation
Inflammation
Local Infection
Systemic Infection
Sepsis
Bacteria interact with the human body throughout the Colonisation Infection Continuum. Every alteration at the early stages,
either the emergence of resistance or the suppression of pathogens, has its effect downstream.
Inflammation
Staphefekt - Acne
Skin Colonization
IrritationAcne
Before Gladskin
Proven S. aureus
After Gladskin
Inflammation
Staphefekt - Acne
Acne
Skin Colonization
Irritation
0
0.5
1
1.5
2
2.5
Acne - severity
Comedones*
Pain*
Cysts*
Papules*
Pustules
(n = 59, mean therapy 37 days, *p<0.02)
Prof. S. Pasmans, J. Totté, Erasmus MC Rotterdam
manuscript submitted
Decreased severity after Staphefekt
Inflammation
0.5
0.75
1
1.25
1.5
1.75
2
Staphefekt - Rosacea
Skin Colonization
Irritation
Rosacea - severity
Dry skin*
Burning
Papules
Persistent
erythema
Edema
(n = 112, mean therapy 37 days, *p<0.01)
Itch* Flushing
Teleangiectasia
Eye symptoms
Pustules*
Suggests role for S. aureus
in inflammatory symptoms
Inflammatory Vascular
Rosacea
Prof. S. Pasmans, J. Totté, Erasmus MC Rotterdam
manuscript submitted
Decreased severity after Staphefekt
Staphefekt - Dermatitis / Eczema
Skin Colonization
Irritation
Inflammation
(Kong, Genome Res. 2012)
Eczema / Dermatitis: S. aureus precedes eczema flare
Staphefekt - Dermatitis / Eczema
S. aureus related Dermatitis / Eczema
Skin Colonization
Irritation
Inflammation
Staphefekt - Furunculosis
Furunculosis
Skin Colonization
Irritation
Inflammation
Local Infection
Before Gladskin
Proven S. aureus
2 weeks 4 weeks
Staphefekt – Prosthetic joint infections
Prosthetic Joint Infections
Skin Colonization
Irritation
Inflammation
Local Infection
Systemic Infection
Staphefekt SA.100
t (minutes)
Decre
ase i
n o
pti
cal
den
sit
y
Staphefekt SA.100 Staphefekt SA.200
t (minutes)
Decre
ase i
n o
pti
cal
den
sit
y
Decre
ase i
n o
pti
cal
den
sit
y
t (minutes)
Staphefekt – 2nd generation
Killing all staphylococci in biofilms:
Necessary for Prosthetic Joint Infections
Selectively killing Staphylococcus aureus
Side effects
Not selective
Resistance induction
Skin Colonization
Irritation
Inflammation
Local Infection
Systemic Infection
Sepsis
Antibiotics
Use is limited
in time & indication
Colonization Infection Continuum
Skin Colonization
Irritation
Inflammation
Local Infection
Systemic Infection
Sepsis
Selective
No resistance induction
Staphefekt / Endolysins
Suitable for long term
suppression therapy
and prophylaxis
“If you’re not prepared to be
wrong, you’ll never come up with
something original”
(Ken Robinson - How Schools Kill Creativity)
10th Medical Innovations Summit | The Royal Society of Medicine | London | Saturday 18th April 2015
Thank you
Mark Offerhaus, CEO MicreosBjorn Herpers, Clinical microbiologist
[email protected] - www.micreos.com